Pod Insights Finshots Daily How Wockhardt solved a problem Indian pharma couldn't About this episode In today’s episode on 4th June 2026, we talk about India’s first homegrown drug and why it took Indian pharma so long to get here.
Book a FREE call with Ditto https://ditto.sh/vx51ji
Transcript 0:01 Speaker 00 Hello folks, you're tuned into Finshots Daily. In today's episode, we talk about India's first homegrown drug and why it took Indian pharma so long to get here.
0:12 Speaker 00 Before we begin, here's a quick word from Team Dito. Life can be unpredictable and if the main earner is not around, the bills won't stop. That's why term insurance is so important. It gives your family a fixed payout so they can cover school fees, EMIs and daily expenses without stress. If you buy it early, you can get a one crore cover for as little as thousand rupees a month and the premium stays the same for your entire policy term. That's real peace of mind at a very small cost. And if you're not sure which plan is right for you, book a free call with Dito. No spam, just honest guidance and we're trusted by over 8 lakh people for their health and term insurance needs. Now, back to the story.
0:54 Speaker 00 India is often called the pharmacy of the world and there's a good reason for that. If you've ever popped a Paracetamol, taken a life-saving antibiotic or received a vaccine, there's a chance it was manufactured by an Indian company. Take a look at what happened when the Novo Nordisk patent for semaglutide expired. Within days, there were at least 15 generics. Generics are simply cheaper versions of the same medicine made after patent protection expires and almost nobody else in the world can make them like we do. For context, today, India supplies medicines to over 200 countries, accounts for roughly 20% of the world's generic medicines and produces more than 60% of the world's vaccines. Which is what makes the next part of the story so surprising.
1:39 Speaker 00 For all our expertise in making medicines, we've rarely been the ones inventing them. Okay, think about it. India is home to thousands of pharmaceutical companies and some of the world's largest drug manufacturers and a talent pool that powers research labs across the globe. Yet, very few drugs are discovered and developed entirely in India. But a few days ago, Walkhart, a Mumbai-based pharma company, became an exception by doing something very few Indian drug makers have done: developing Zynic.
2:10 Speaker 00 Homegrown antibiotic and earning global recognition for it. A little sidebar here, Indian companies have developed homegrown drugs before Walkhart, but most stayed largely India focused and never turned into major global success stories. Take Zytus' Saraglitazar, approved in India in 2013. It's often described as the first NCE, that's new chemical entity or essentially a brand new active ingredient, never approved for human use before. Discovered and developed by an Indian company to reach the market. But despite the milestone, it remained largely a domestic story rather than becoming a global blockbuster. Which makes you ask, why did a country that became exceptionally good at manufacturing medicines, take so long to create one of its own?
2:54 Speaker 00 The answer lies in a decades old decision that helped build India's pharmaceutical industry into a global powerhouse. But that same decision may have also made drug discovery one of the hardest bets an Indian company could make. To understand why, we need to go back to 1970 with the Indian Patent Act. At the time, foreign pharmaceutical companies dominated India's drug market and medicines were often too expensive for ordinary Indians. So the government introduced a new patent regime that recognized process patents for medicines. In simple terms, if an Indian company could figure out how to reverse engineer and manufacture a drug, it could legally produce and sell it even if the original molecule had been discovered elsewhere. The policy worked amazingly well.
3:35 Speaker 00 Indian drug makers didn't need to spend billions discovering new molecules when manufacturing proven ones was faster, cheaper and far less risky. That also meant medicines became more affordable, nurtured domestic drug makers, and eventually turned India into the world's generic drug powerhouse. If you think about it, this also indirectly gave companies less reason to take on the harder challenge of developing their own drugs. In a way, India's pharmaceutical industry became too successful for its own good. For decades, Indian drug makers could simply take a medicine discovered elsewhere, manufacture it at scale, sell it at a fraction of the cost and still make healthy profits. Drug discovery, on the other hand, was a harder pitch to sell to the board and investors. Every rupee they would spend on it is a rupee not spent expanding labs, making new generics or making
4:20 Speaker 00 The current business stronger. In other words, companies must fund innovation by sacrificing profits from the very model that made them successful in the first place. And that's a difficult trade off. A generated drug can start generating revenue within a few years, but the same can't be said for a new molecule. And that's what makes Walkhart's breakthrough so interesting. Inventing a new drug today is a little like buying lottery tickets that cost millions of dollars each. Most never amount to anything, even the winning ones can take over a decade to pay off. On average, pharmaceutical companies spend billions of dollars and ten to fifteen years bringing a single drug to market and most still fail. And Walkhart had that stubbornness.
5:02 Speaker 00 For over twenty seven years, a team of scientists in Mumbai quietly worked on something the rest of the industry had largely given up on. Discovering new antibiotics. Their target was antimicrobial resistance or AMR. It's what happens when bacteria evolved to outsmart the drugs meant to kill them. Bacterial AMR was directly responsible for one point two million deaths globally in twenty nineteen and contributed to nearly five million more. And yet globally, new antibiotic development has nearly come to a full stop. The financial incentives simply aren't there. Most large pharmaceutical companies have exited antibiotic research entirely. Despite that, Walkhart kept going anyway. Back in November twenty twenty four, they launched Naphithromycin.
5:48 Speaker 00 I hope I'm saying that right. And it was marketed as McNaf. Which became India's first indigenously discovered antibiotic in over three decades. Developed with support from Biotechnology Industry Research Assistance Council, that is B I R A C. Naphithromycin targets bacterial pneumonia caused by drug resistant bacteria. For doctors, the appeal was simple. A treatment that worked faster, required fewer doses and could help fight bacteria that were becoming increasingly resistant to existing drugs. But Naphithromycin was only the beginning. The biggest story is of Xanax. Built to tackle some of the world's most dangerous drug resistant infections, Xanax goes
6:30 Speaker 00 After the very bacteria that have learned how to survive our best antibiotics. In clinical trials, the drug demonstrated remarkably high efficacy against pathogens that have become increasingly difficult to treat with existing antibiotics. And this was in some niche scientific curiosity. Zynic achieved a staggering ninety-six point eight efficacy rate in phase three trials and quickly caught the attention of regulators in both the US and Europe. In fact, Walkhart became the first Indian pharmaceutical company to seek US FDA approval for a drug discovered and developed entirely in India. Walkhart expects no competition for this drug worldwide for at least the next fifteen years as there is no similar drug in research pipelines anywhere.
7:15 Speaker 00 Because while India has a world-class ecosystem for making medicines, not many companies want to cannibalize it for a risky breakthrough. But Walkhart did and it kept reinvesting its profits into making this homegrown drug. That's what makes Zynic so remarkable. It proves today that not only can we make the world's best medicines but also invent them. And the opportunity ahead is huge. Right now, India has captured just three percent of the world's pharma market by value and with more homegrown drugs, we could capture more value, whereas the volume already sits in our favor. Besides, things may have also started to change as pharma giants like Sun Pharma and Glenn Mark are already exploring how AI can speed up parts of the drug discovery process
8:01 Speaker 00 and reduce the chances of costly failures. If these technologies can lower the time, cost and risk, the next Indian pharma giant may not have to spend another twenty-seven years proving what Indian pharma is capable of. Alright folks, I will see you in the next one.
8:17 Speaker 00 Thank you for listening to today's episode. And if you want to share your feedback or suggestions, do drop us an email to [email protected] . Until next time.
Previous India's industrial growth explained Next Rajesh Exports' House of Cards? Page updated November 9, 2026 · transcript and summary are machine-generated